HB3682 102ND GENERAL ASSEMBLY

LRB102 11453 JLS 16787 b

102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022
HB3682

Introduced 2/22/2021, by Rep. Joe Sosnowski

SYNOPSIS AS INTRODUCED:

New Act

Creates the COVID-19 Workplace Vaccination Program Limitation Act. Provides that it is unlawful for an employer in the State of Illinois to create, implement, or otherwise enforce a workplace vaccination program that requires any employee to demonstrate to the employer that he or she has received a vaccine that was approved under emergency use authorization by the United States Food and Drug Administration. Provides for repeal of the Act on January 1, 2023. Effective immediately.

FISCAL NOTE ACT MAY APPLY

A BILL FOR

AN ACT concerning employment.

Be it enacted by the People of the State of Illinois, represented in the General Assembly:

Section 1. Short title. This Act may be cited as the COVID-19 Workplace Vaccination Program Limitation Act.

Section 5. Purpose. It is the purpose of this Act to allow individuals to have the autonomy to make the decision of whether or not to receive a vaccination that was approved by the United States Food and Drug Administration to be used under emergency use authorization for treatment of COVID-19. The fact that the vaccines made available amid the global pandemic have been granted emergency use authorization means that both regulatory bodies and industry experts have not been allotted sufficient time to study either the short-term and long-term effects that may arise from the administration of vaccinations authorized for emergency use. Therefore, the State is compelled to prohibit employers from requiring that employees receive a vaccine that has been approved under emergency use authorization as a condition of employment.

Section 10. Prohibition. It is unlawful for an employer in the State of Illinois to create, implement, or otherwise enforce a workplace vaccination program that requires an employee to demonstrate to the employer that he or she has received a vaccine that was approved under emergency use authorization by the United States Food and Drug Administration, under the Administration's power outlined in Section 564 of the Federal Food, Drug, and Cosmetic Act, for protection against COVID-19.

Section 95. Repeal. This Act is repealed on January 1, 2023.

Section 99. Effective date. This Act takes effect upon becoming law.